metoclopramide has been researched along with Movement Disorders in 21 studies
Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.
metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.
Movement Disorders: Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tardive tremor is a 3-5 Hz bilateral resting and action tremor, associated with the use of dopamine receptor blocking drugs, accompanied by other tardive movement disorders and responsive to tetrabenazine or clozapine." | 7.78 | Sensory trick with metoclopramide-associated tardive tremor. ( Shprecher, D, 2012) |
| " Although known to interfere with central dopamine mechanisms, it is frequently used in Parkinson's disease to prevent levodopa-induced nausea and vomiting." | 5.04 | Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias. ( Marsden, CD; Parkes, JD; Tarsy, D, 1975) |
| "Metoclopramide, the only drug approved by the FDA for treatment of diabetic gastroparesis, but used off-label for a variety of other gastrointestinal indications, has many potentially troublesome adverse neurologic effects, particularly movement disorders." | 4.83 | Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide. ( Jankovic, J; Pasricha, PJ; Pehlivanov, N; Sugumar, A, 2006) |
| "We examined the effects of the black box warning about the risk of tardive dyskinesia (TD) with chronic use of metoclopramide on management of gastroparesis within a single clinical practice, and on reporting of adverse events." | 3.79 | The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits. ( Deepak, P; Devi, R; Du, H; Ehrenpreis, ED; Leikin, JB; Sifuentes, H, 2013) |
| "Tardive tremor is a 3-5 Hz bilateral resting and action tremor, associated with the use of dopamine receptor blocking drugs, accompanied by other tardive movement disorders and responsive to tetrabenazine or clozapine." | 3.78 | Sensory trick with metoclopramide-associated tardive tremor. ( Shprecher, D, 2012) |
| "Plasma levels of beta-endorphin (beta-EP) and prolactin (PRL) were measured in 5 girls with Rett syndrome and in a control group before and after giving 10 mg metoclopramide i." | 3.67 | Plasma endorphins in Rett syndrome: preliminary data. ( Bernasconi, S; Facchinetti, F; Genazzani, AR; Nalin, A; Petraglia, F; Zappella, M, 1986) |
| "The long-term use of many antipsychotic medications carries a risk of tardive dyskinesia in a small proportion of patients." | 1.38 | Cell membrane lytic action of metoclopramide and its relation to tardive dyskinesia. ( Lai, TK; Liu, F; Seeman, P, 2012) |
| "Metoclopramide was discontinued and diphenhydramine 50 mg was initially administered intravenously followed with 25 mg orally every 4 hours as needed." | 1.38 | Tardive dyskinesia after short-term treatment with oral metoclopramide in an adolescent. ( Karimi Khaledi, M; Shelton, CM; Suda, KJ, 2012) |
| "Metoclopramide (MET) has long been used as a neuroleptic and antiemetic drug in clinical practice." | 1.32 | Metoclopramide attenuates iminodipropionitrile-induced oxidative stress and neurobehavioral toxicity in rats. ( Ahmad Khan, H; Al Deeb, S; Al Moutaery, K; Tariq, M, 2004) |
| "Metoclopramide is an effective non-phenothiazine antiemetic that acts, in part, by blockade of the dopamine receptors." | 1.27 | Prolonged metoclopramide-induced dyskinetic reaction. ( Leopold, NA, 1984) |
| "The overall reporting rate for dystonia and dyskinesia was 28." | 1.27 | Extrapyramidal reactions with metoclopramide. ( Bateman, DN; Rawlins, MD; Simpson, JM, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (42.86) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 4 (19.05) | 29.6817 |
| 2010's | 7 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ehrenpreis, ED | 1 |
| Deepak, P | 1 |
| Sifuentes, H | 1 |
| Devi, R | 1 |
| Du, H | 1 |
| Leikin, JB | 1 |
| Wijemanne, S | 1 |
| Jankovic, J | 2 |
| Evans, RW | 1 |
| Chen, S | 1 |
| Seeman, P | 2 |
| Liu, F | 2 |
| Buscombe, C | 1 |
| Alusi, SH | 1 |
| Kahn, DA | 1 |
| Lai, TK | 1 |
| Karimi Khaledi, M | 1 |
| Suda, KJ | 1 |
| Shelton, CM | 1 |
| Shprecher, D | 1 |
| Ahmad Khan, H | 1 |
| Al Deeb, S | 1 |
| Al Moutaery, K | 1 |
| Tariq, M | 1 |
| Pasricha, PJ | 1 |
| Pehlivanov, N | 1 |
| Sugumar, A | 1 |
| Leopold, NA | 1 |
| Schroeder, JA | 1 |
| Wolfe, WM | 1 |
| Thomas, MH | 1 |
| Tsueda, K | 1 |
| Heine, MF | 1 |
| Loyd, GE | 1 |
| Vogel, RL | 1 |
| Hood, GA | 1 |
| Cosentino, C | 1 |
| Torres, L | 1 |
| Scorticati, MC | 1 |
| Micheli, F | 1 |
| Jenner, P | 1 |
| Marsden, CD | 2 |
| Tarsy, D | 1 |
| Parkes, JD | 1 |
| Melmed, S | 1 |
| Bank, H | 1 |
| Walsh, CH | 1 |
| Facchinetti, F | 1 |
| Zappella, M | 1 |
| Nalin, A | 1 |
| Petraglia, F | 1 |
| Bernasconi, S | 1 |
| Genazzani, AR | 1 |
| Bateman, DN | 1 |
| Rawlins, MD | 1 |
| Simpson, JM | 1 |
| Chouza, C | 1 |
| Caamano, JL | 1 |
| Romero, S | 1 |
| Lorenzo, J | 1 |
| Feres, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot, Randomized, Double-blind, Placebo-controlled Trial of Promethazine for Treatment of Diabetic Gastroparesis.[NCT02130622] | Phase 2 | 3 participants (Actual) | Interventional | 2014-07-31 | Terminated (stopped due to Lack of recruitment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for metoclopramide and Movement Disorders
| Article | Year |
|---|---|
Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide.
Topics: Dopamine Antagonists; Drug Utilization Review; Gastroparesis; Humans; Metoclopramide; Movement Disor | 2006 |
The substituted benzamides--a novel class of dopamine antagonists.
Topics: Animals; Antiemetics; Antipsychotic Agents; Behavior, Animal; Benzamides; Brain; Dopamine; Dopamine | 1979 |
2 trials available for metoclopramide and Movement Disorders
| Article | Year |
|---|---|
The effect of intravenous ranitidine and metoclopramide on behavior, cognitive function, and affect.
Topics: Adult; Affect; Behavior; Cognition; Double-Blind Method; Drug Interactions; Female; Humans; Injectio | 1994 |
Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias.
Topics: Aged; Carbidopa; Clinical Trials as Topic; Drug Evaluation; Drug Interactions; Drug Therapy, Combina | 1975 |
17 other studies available for metoclopramide and Movement Disorders
| Article | Year |
|---|---|
The metoclopramide black box warning for tardive dyskinesia: effect on clinical practice, adverse event reporting, and prescription drug lawsuits.
Topics: Adverse Drug Reaction Reporting Systems; Domperidone; Dopamine Antagonists; Drug Labeling; Gastropar | 2013 |
Movement Disorders From the Use of Metoclopramide and Other Antiemetics in the Treatment of Migraine.
Topics: Adult; Dihydroergotamine; Dopamine Agonists; Dopamine D2 Receptor Antagonists; Expert Testimony; Fem | 2016 |
Metoclopramide: tardive dyskinesia. Beware long-term use.
Topics: Dyskinesia, Drug-Induced; Humans; Metoclopramide; Movement Disorders | 2009 |
Antipsychotic drug binding in the substantia nigra: an examination of high metoclopramide binding in the brains of normal, Alzheimer's disease, Huntington's disease, and Multiple Sclerosis patients, and its relation to tardive dyskinesia.
Topics: Alzheimer Disease; Animals; Antipsychotic Agents; Dopamine Antagonists; Dose-Response Relationship, | 2011 |
A biopsychosocial approach to improving quality of life in tardive dystonia.
Topics: Antiemetics; Dyskinesia, Drug-Induced; Female; Humans; Metoclopramide; Middle Aged; Movement Disorde | 2010 |
Cell membrane lytic action of metoclopramide and its relation to tardive dyskinesia.
Topics: Antipsychotic Agents; Erythrocyte Membrane; Hemolysis; Humans; Metoclopramide; Movement Disorders | 2012 |
Tardive dyskinesia after short-term treatment with oral metoclopramide in an adolescent.
Topics: Administration, Oral; Adolescent; Age Factors; Antiemetics; Diphenhydramine; Drug Administration Sch | 2012 |
Sensory trick with metoclopramide-associated tardive tremor.
Topics: Adrenergic Uptake Inhibitors; Aged; Blepharospasm; Cervical Vertebrae; Dopamine Antagonists; Humans; | 2012 |
Metoclopramide attenuates iminodipropionitrile-induced oxidative stress and neurobehavioral toxicity in rats.
Topics: Animals; Female; Metoclopramide; Motor Activity; Movement Disorders; Nitriles; Oxidative Stress; Rat | 2004 |
Prolonged metoclopramide-induced dyskinetic reaction.
Topics: Acute Disease; Adult; Benztropine; Female; Humans; Metoclopramide; Movement Disorders; Nausea; Time | 1984 |
Movement disorders secondary to adulterated medication.
Topics: Adult; Aged; Aged, 80 and over; Argentina; Drug Contamination; Female; Humans; Levodopa; Male; Metoc | 2000 |
Letter: Metoclopramide and facial dyskinesia.
Topics: Adult; Basal Ganglia Diseases; Face; Facial Expression; Female; Humans; Male; Metoclopramide; Moveme | 1975 |
Letter: Involuntary facial movements.
Topics: Benztropine; Female; Humans; Metoclopramide; Movement Disorders | 1975 |
Plasma endorphins in Rett syndrome: preliminary data.
Topics: Adolescent; beta-Endorphin; beta-Lipotropin; Child; Child, Preschool; Endorphins; Female; Humans; In | 1986 |
Extrapyramidal reactions with metoclopramide.
Topics: Adolescent; Adult; Age Factors; Aged; Child; Child, Preschool; Dystonia; Female; Humans; Infant; Inf | 1985 |
Extrapyramidal effects of benzamides.
Topics: Basal Ganglia Diseases; Benzamides; Dyskinesia, Drug-Induced; Humans; Metoclopramide; Movement Disor | 1985 |
Letter: Pyridoxine in parkinsonism.
Topics: Dihydroxyphenylalanine; Drug Antagonism; Drug Interactions; Humans; Metoclopramide; Movement Disorde | 1973 |